Medtronic Eyes Proactive Care With Edema Monitoring, MRI-Safe CRM
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is preparing a premarket approval application for its InSync Sentry cardiac resynchronization therapy device/defibrillator with edema monitoring
You may also be interested in...
Medtronic InSync II Protect
Resynchronization defibrillator (CRT), set to launch in Europe this quarter, is among cardiac rhythm management devices previewed during a Feb. 12 earnings call. InSync Protect "will offer unique programming efficiencies and tailored ICD therapy that leverages new clinical findings to minimize unnecessary shocks," CEO Art Collins claims. Medtronic has four CRT-D devices in the pipeline, beginning with InSync Maximo, scheduled for U.S. release this year (1"The Gray Sheet" Jan. 19, 2004, p. 5). Also set for domestic launch this year are six new ICD models, including the Intrinsic "core ICD," and two pacemaker platforms - EnPulse 2 by summer and EnRhythm by year-end...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.